Posts

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

Lilly, BMS, and Incyte have each announced new AI‑focused deals to deepen artificial intelligence integration across drug discovery, development, and enterprise operations. Bristol Myers Squibb (BMS) has struck a strategic agreement with Anthropic to deploy the Claude AI model across more than 30,000 employees, embedding it into research, clinical development, manufacturing, commercial, and corporate workflows. Eli Lilly is integrating its AI engine Lilly TuneLab into Collaborative Drug Discovery’s CDD Vault, enabling biotechs to access Lilly’s proprietary data inside a secure data‑sharing environment. Incyte has expanded its partnership with Genesis Molecular AI with a $120 million upfront package ($80 million cash plus $40 million equity) and potential milestone payments that could exceed $1 billion across five initial targets. Sources: Incyte inks deal with Edison to train AI through drug discovery Eli Lilly to present at Bernstein's Strategic D... | Pluang AI Oppo...

Amgen’s Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

With Voxzogo under pressure, BioMarin touts trial win in label expansion bid

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

GHO Capital and CBC Group to merge into world’s largest dedicated healthcare investor

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa, a First‑in‑Class Hybrid Drug for Parkinson’s Disease

Labcorp rolls out AI-powered mobile app to interpret test results

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop

AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial